La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Axsome Therapeutics Gestion
Gestion contrôle des critères 2/4
Le PDG Axsome Therapeutics' est Herriot Tabuteau, nommé en Jan2012, a un mandat de 12.58 ans. La rémunération annuelle totale est $ 9.90M, composée du salaire de 7.6% et des bonus 92.4%, y compris les actions et options de la société. détient directement 0.015% des actions de la société, d'une valeur de $ 622.91K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.3 ans et 9.7 ans.
Informations clés
Herriot Tabuteau
Directeur général
US$9.9m
Rémunération totale
| Pourcentage du salaire du PDG | 7.6% |
| Durée du mandat du directeur général | 12.6yrs |
| Propriété du PDG | 0.02% |
| Durée moyenne d'occupation des postes de direction | 6.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9.7yrs |
Mises à jour récentes de la gestion
Recent updates
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$309m |
| Mar 31 2024 | n/a | n/a | -US$296m |
| Dec 31 2023 | US$10m | US$750k | -US$239m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$8m | US$685k | -US$187m |
| Sep 30 2022 | n/a | n/a | -US$160m |
| Jun 30 2022 | n/a | n/a | -US$150m |
| Mar 31 2022 | n/a | n/a | -US$141m |
| Dec 31 2021 | US$8m | US$685k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$100m |
| Dec 31 2020 | US$7m | US$575k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$90m |
| Dec 31 2019 | US$5m | US$435k | -US$68m |
| Sep 30 2019 | n/a | n/a | -US$53m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$435k | -US$31m |
| Sep 30 2018 | n/a | n/a | -US$29m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$1m | US$435k | -US$29m |
Rémunération vs marché: La rémunération totale de Herriot ($USD 9.90M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.76M ).
Rémunération et revenus: La rémunération de Herriot a augmenté alors que l'entreprise n'est pas rentable.
PDG
Herriot Tabuteau (56 yo)
12.6yrs
Titularisation
US$9,896,629
Compensation
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 12.6yrs | US$9.90m | 0.015% $ 636.1k | |
| Chief Financial Officer | 6.3yrs | US$3.57m | 0.088% $ 3.7m | |
| Chief Operating Officer | 8.8yrs | US$4.04m | 0.012% $ 508.9k | |
| General Counsel & Secretary | 2.7yrs | US$3.06m | 0% $ 0 | |
| Executive VP & Head of Commercial | less than a year | pas de données | pas de données |
6.3yrs
Durée moyenne de l'emploi
46.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de AXSM est chevronnée et expérimentée (ancienneté moyenne 6.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 12.6yrs | US$9.90m | 0.015% $ 636.1k | |
| Independent Lead Director | 9.7yrs | US$400.34k | 0.35% $ 14.8m | |
| Independent Director | 9.7yrs | US$405.34k | 0.021% $ 906.4k | |
| Independent Director | less than a year | US$417.48k | 0% $ 0 | |
| Independent Director | 9.7yrs | US$427.84k | 0.030% $ 1.3m |
9.7yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de AXSM sont considérés comme expérimentés (ancienneté moyenne 9.7 ans).